| 000 | 01352 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250516142720.0 | ||
| 264 | 0 | _c20131031 | |
| 008 | 201310s 0 0 eng d | ||
| 022 | _a1179-1969 | ||
| 024 | 7 |
_a10.1007/s40266-013-0077-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFrampton, James E | |
| 245 | 0 | 0 |
_aRanibizumab: a review of its use in the treatment of neovascular age-related macular degeneration. _h[electronic resource] |
| 260 |
_bDrugs & aging _cMay 2013 |
||
| 300 |
_a331-58 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xeconomics |
| 650 | 0 | 4 |
_aChoroidal Neovascularization _xdrug therapy |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aEurope |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMacular Degeneration _xdrug therapy |
| 650 | 0 | 4 | _aMulticenter Studies as Topic |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aRanibizumab |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 773 | 0 |
_tDrugs & aging _gvol. 30 _gno. 5 _gp. 331-58 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s40266-013-0077-9 _zAvailable from publisher's website |
| 999 |
_c22624589 _d22624589 |
||